Press Release FeedGet the RSS feed
Menu

Business Wire

Dyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress of the World Muscle Society

Business Wire

Late-breaking poster shows that AI-designed capsids that engage multiple cell-entry receptors deliver improved muscle transduction with low liver biodistribution in mice and non-human primates at 5e12 vg/kg, a dose 20-fold lower than typical doses used in the clinic

WATERTOWN, Mass., October 02, 2026--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced new preclinical data on its next-generation muscle capsids at the 31st International Congress of the World Muscle Society (WMS), taking place September 29 to October 3, 2026 in Hiroshima, Japan.

The late-breaking poster introduces a class of AI-designed multi-mechanism capsids that engage more than one cell-entry receptor. Dyno characterized these capsids in mice and non-human primates (NHPs) at a dose of 5e12 vg/kg. Existing muscle capsids often require doses near 1e14 vg/kg, 20-fold higher than that used by Dyno, to achieve therapeutic expression. Such high doses carry safety risks driven by off-target delivery to the liver.

Two lead capsids were designed using Dyno's AI-powered platform to optimize multiple properties, including cross-species translatability. Each capsid demonstrated enhanced muscle delivery and improved liver detargeting following systemic administration in mice and NHPs.

  • In mice at 5e12 vg/kg, both capsids demonstrated ~2-fold higher biodistribution and transduction across measured skeletal muscles compared with MyoAAV-4E (Tabebordbar et al., Cell, 2021).

  • In NHPs at 5e12 vg/kg, one capsid demonstrated ~20-fold higher biodistribution and ~40-fold higher transduction across skeletal muscles compared with MyoAAV-4E. The other capsid also showed higher skeletal muscle tropism than MyoAAV-4E, together with ~10-fold lower liver biodistribution.

The high muscle potency of these multi-mechanism capsids and diminished liver exposure at clinically relevant doses enable safer advancement of more gene therapies for muscular diseases. These capsids also accelerate preclinical development because they support disease-model testing in mice and translational efficacy and safety assessment in NHPs, the best existing model to predict biodistribution in humans.

Presentation details are as follows:

Late-Breaking Poster Presentation

Title: AI-guided engineering of multiple-mechanism AAV capsids enables therapeutic muscle delivery and facilitates drug development through cross-species translation in mouse and NHP

  1. EnergyWorld’s First Commercial Ship-to-Ship Green Ammonia Bunkering Completed in Zhoushan, Zhejiang, ChinaZHOUSHAN, China, October 18, 2026--On October 13, 2026, the world's first commercial ship-to-ship bunkering of green ammonia fuel was completed at an anchorage in Zhoushan Port, Zhejiang Province, China. A total of 1,000 tonnes of green ammonia from the HyFlow-1 Songyuan Hydrogen Energy Industrial Park
  2. SaaSThe Prostate Cancer FoundationProstate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i
  3. FinanceAlign Technology, Inc.Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent CourtCompanies: Align TechnologySAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner syst
  4. AISyncra and Neumetry Partner to Build AI-Powered Readiness Platform for Teenage Athletes and Their CoachesSmart ring data meets FDA-cleared physiological AI to help coaches see which athletes are ready to compete, and which need rest LAS VEGAS & SAN JOSE, Calif., October 17, 2026--Syncra Labs Inc., maker of the Syncra smart ring, and Neumetry Medical, Inc., developer of an FDA-cleared predictive health pla
  5. HealthcareAIDS Healthcare FoundationAHF Commemorates 40 Years of Global Impact During Annual World AIDS Day Concert Celebration Featuring Ricky MartinLOS ANGELES, October 16, 2026--AIDS Healthcare Foundation (AHF) , the world's largest, non-profit public health organization providing direct HIV/ADS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. Continu
  6. Real estateKBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6)NEW YORK, October 16, 2026--KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6), a $250.6 million non-prime RMBS transaction. The underlying collateral, comprised of 381 residential mortgages, and includes a meaningful conce